Literature DB >> 12841130

Interventional treatment of multiple vascular involvement in young male with heterozygous familial hypercholesterolemia.

J C Lubanda1, S Simek, A Linhart, M Aschermann, R Ceska.   

Abstract

We report a case of 31 year old man with heterozygous familial hypercholesterolemia and excessive tobacco use leading to acute myocardial infarction as the first manifestation of premature atherosclerosis. The patvent was treated by primary PTCA of occluded first marginal artery and at this time an attempt of recanalisation of occluded LAD was unsuccessful. The patient was referred for mini coronary bypass graft of the LIMA to LAD. During evaluation of carotid arteries we found a significant stenosis of the left internal carotid artery and occlusion of the left subclavian artery which made the use of LIMA unsuitable. Therefore, another attempt of PTCA of the occluded LAD was performed, this time with success. Hence PTA of the occluded subclavian artery was performed with good result. The patient was treated with the standard therapy of CAD and combined lipid lowering agents with significant reduction of plasma cholesterol. However, 2 years after the first MI, he suddenly died after swimming at the age of 31. In this patient the risk of premature CAD was increased by the presence of another powerful risk factor--the excessive tobacco use. Acute physical exercise probably acted as a trigger of acute coronary events at the time of both MI. Interventional methods were very effective in the treatment of multiple atherosclerotic lesions in this patient and provided significant relief of symptoms. Treatment of heterozygous FH is briefly discussed in this article.

Entities:  

Mesh:

Year:  2003        PMID: 12841130

Source DB:  PubMed          Journal:  Cas Lek Cesk        ISSN: 0008-7335


  1 in total

1.  Endovascular treatment of multiple severe atherosclerotic stenoses with cerebral hypoperfusion. Case report.

Authors:  N Uchiyama; Y Okada; S Higashi
Journal:  Interv Neuroradiol       Date:  2006-06-15       Impact factor: 1.610

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.